Bowers Aaron, Meyer Chase, Tritz Daniel, Cook Courtney, Fuller Kaleb, Smith Caleb, Diener Brian, Vassar Matt
College of Osteopathic Medicine, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma.
College of Osteopathic Medicine, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma.
J Surg Res. 2018 Apr;224:233-239. doi: 10.1016/j.jss.2017.11.061. Epub 2018 Feb 22.
Recent studies have highlighted the risk of bias and the fragility of results in randomized controlled trials (RCTs). The aim of our study was to evaluate the clinical practice guidelines created by the Society for Gastrointestinal and Endoscopic Surgeons (SAGES) for fragility, statistical power, and risk of bias.
We screened the SAGES clinical practice guideline references for qualifying RCTs. RCTs were assessed for risk of bias using the Cochrane Collaboration Risk of Bias tool 2.0. We used the fragility index and fragility quotient to evaluate the robustness of trial results and conducted a power analysis using G*Power to determine if trials were adequately powered.
Twenty-two (40.7%) of the 54 trials that we assessed were rated as having a high risk of bias, 17 (31.5%) were rated as having a low risk of bias, and 15 (27.8%) were rated as having some concerns. The median fragility index was 2.5 (interquartile range 1-7). The median fragility quotient was 0.021 (interquartile range 0.003-0.045). Mean sample size was 108, and the mean loss to follow-up was eight patients. Eight of 33 trials (24.2%) were found to be underpowered according to the sample size used in the primary outcome.
Guidelines created by SAGES are supported by RCTs that are frequently fragile or underpowered or have a high risk of bias. Future RCTs should utilize the Consolidated Standards of Reporting Trials statement, implement strategies to minimize loss to follow-up, and use properly powered sample sizes.
近期研究强调了随机对照试验(RCT)中存在的偏倚风险和结果的脆弱性。我们研究的目的是评估胃肠与内镜外科医师协会(SAGES)制定的临床实践指南在脆弱性、统计效能和偏倚风险方面的情况。
我们筛选了SAGES临床实践指南参考文献中的合格RCT。使用Cochrane协作网偏倚风险工具2.0评估RCT的偏倚风险。我们使用脆弱性指数和脆弱性商数来评估试验结果的稳健性,并使用G*Power进行效能分析,以确定试验是否具有足够的效能。
我们评估的54项试验中,22项(40.7%)被评为具有高偏倚风险,17项(31.5%)被评为具有低偏倚风险,15项(27.8%)被评为存在一些问题。脆弱性指数的中位数为2.5(四分位间距1 - 7)。脆弱性商数的中位数为0.021(四分位间距0.003 - 0.045)。平均样本量为108,平均失访患者数为8例。根据主要结局所使用的样本量,33项试验中有8项(24.2%)被发现效能不足。
SAGES制定的指南所依据的RCT往往存在脆弱性或效能不足,或者具有高偏倚风险。未来的RCT应采用《报告试验的统一标准》声明,实施策略以尽量减少失访,并使用具有适当效能的样本量。